Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03235297 · ClinicalTrials.gov registry record
Effects of Altitude on Single-Breath Diffusing Capacity for Carbon Monoxide
A clinical trial, sponsored by Intermountain Health Care.
- Completed
- Registry status
- 23
- Enrollment target
NCT03235297: Completed study, sponsored by Intermountain Health Care.
NCT03235297 is a clinical trial that has completed, run by Intermountain Health Care. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03235297 has completed, sponsored by Intermountain Health Care.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to further understand the effects of altitude on the physiology of gas exchange in the pulmonary microcirculation in normal subjects and in people with chronic obstructive pulmonary disease (COPD) measured as the single-breath diffusing capacity for carbon monoxide (DLCOsb). The study will determine a mathematical formula to allow for altitude corrections in both study populations to be used clinically in pulmonary labs.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-08-10 |
| Est. Completion | 2019-07-01 |
What the finished NCT03235297 record still lists
NCT03235297 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03235297 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03235297 about?
NCT03235297 is a clinical study titled "Effects of Altitude on Single-Breath Diffusing Capacity for Carbon Monoxide". The purpose of this study is to further understand the effects of altitude on the physiology of gas exchange in the pulmonary microcirculation in normal subjects and in people with chronic obstructive pulmonary disease (COPD) measured as the single-breath diffusing capacity for carbon monoxide (DLCO...
What is the current status of trial NCT03235297?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2017-08-10. Estimated completion is 2019-07-01.
Who is sponsoring clinical trial NCT03235297?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI